Holmes, Jr., Laurens (Nemours Healthcare System, Wilmington, Delawar
SARS-CoV2 (COVID-19) Pandemic Control and Prevention
An Epidemiological Perspective
57,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
Melden Sie sich
hier
hier
für den Produktalarm an, um über die Verfügbarkeit des Produkts informiert zu werden.
Holmes, Jr., Laurens (Nemours Healthcare System, Wilmington, Delawar
SARS-CoV2 (COVID-19) Pandemic Control and Prevention
An Epidemiological Perspective
- Broschiertes Buch
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemic to enable better measures for preventions and control.
Andere Kunden interessierten sich auch für
- Infection Prevention and Control113,99 €
- Mark HonigsbaumThe Pandemic Century11,99 €
- Jim LynchWhat Is Life and How Might It Be Sustained?14,99 €
- John Morris (University of Sydney, NSW, Australia)Neurological Clinical Examination130,99 €
- Mark HonigsbaumThe Pandemic Century: One Hundred Years of Panic, Hysteria, and Hubris26,99 €
- Eric Klinenberg202016,99 €
- Eric Klinenberg202026,99 €
-
-
-
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemic to enable better measures for preventions and control.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 166
- Erscheinungstermin: 29. September 2023
- Englisch
- Abmessung: 174mm x 247mm x 14mm
- Gewicht: 350g
- ISBN-13: 9781032543550
- ISBN-10: 1032543558
- Artikelnr.: 68101254
- Verlag: Taylor & Francis Ltd
- Seitenzahl: 166
- Erscheinungstermin: 29. September 2023
- Englisch
- Abmessung: 174mm x 247mm x 14mm
- Gewicht: 350g
- ISBN-13: 9781032543550
- ISBN-10: 1032543558
- Artikelnr.: 68101254
Laurens (Larry) Holmes, Jr. is an immunologist and infectious disease specialist, and obtained his doctoral degree in cancer epidemiology and biostatistics from the University of Texas, Health Sciences Center at Houston. He is a Principal Translational Research Scientist, a former Founding Director of the Nemours Paediatric Translational Health Disparities Science research, training and education program, Wilmington, DE (USA), a leading proponent of epigenomic epidemiology in clinical medicine and public health and Affiliate professor of molecular epidemiology and clinical trials at the Biological Sciences Department at the University of Delaware, Newark, DE (USA), Co-founder and Director of Global Health Equity Foundation (GHEF-USA) and Founding Director of Lawhols International Scientific Research Consulting, LIS-RC (USA). Professor Holmes is currently a Director of the Graduate Public Health Program (Epidemiology and Global Health), Public Health & Allied Health Sciences Department, Wesley College-Delaware State University, Dover, DE (USA).
1.Immuno
epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno
epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS
CoV2 (COVID
19): Pandemic and Public Health Emergency Response. 4.SARS
CoV2 Mutation: Immuno
Epidemiologic and Socio
Epidemiologic Response. 5.COVID
19 Pandemic: Epidemic Curve Down
Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS
CoV2 Transmission & COVID
19 Fetal Survivability: Immuno
epidemiologic Perspective. 7.SARS
CoV2 (COVID
19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID
19 Pandemic Global Health Equity Transformation. 9.SARS
CoV2 "Re
emergence" as COVID
19 (2): Translational Public Health and Immuno
epidemiologic Response. 10 .SARS
CoV2 (COVID
19) Viral Dynamics Control. 11.Immune System Senescence in SARS
CoV2 Transmission and COVID
19 Clinical Manifestations, Severity and Complications. 12.SARS
CoV2 Exponential Spread and COVID
19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS
CoV2 (COVID
19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS
CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS
CoV2 (COVID
19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS
CoV2 (COVID
19) Novel Variants (DELTA), Vaccine Cross
effectiveness and Durability. 17.SARS
CoV2 (COVID
19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities
Blacks/African Americans (AA). 18.SARS
CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case
positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health
related Event in SARS
CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS
CoV2 (COVID
19) Vaccine Effectiveness and Durability in Immunogenic
related Comorbidities (Multiple Myeloma). 21.SARS
CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS
CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS
CoV2 (COVID
19) Morbidity Implication in Chronic Disease (Type II Diabetes
T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS
CoV2 (COVID
19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS
CoV2 (COVID
19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS
COV
2 (COVID
19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS
CoV2 and COVID
19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo
clustering Differentials in SARS
CoV
2 (COVID
19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno
epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS
CoV2 (COVID
19): Pandemic and Public Health Emergency Response. 4.SARS
CoV2 Mutation: Immuno
Epidemiologic and Socio
Epidemiologic Response. 5.COVID
19 Pandemic: Epidemic Curve Down
Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS
CoV2 Transmission & COVID
19 Fetal Survivability: Immuno
epidemiologic Perspective. 7.SARS
CoV2 (COVID
19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID
19 Pandemic Global Health Equity Transformation. 9.SARS
CoV2 "Re
emergence" as COVID
19 (2): Translational Public Health and Immuno
epidemiologic Response. 10 .SARS
CoV2 (COVID
19) Viral Dynamics Control. 11.Immune System Senescence in SARS
CoV2 Transmission and COVID
19 Clinical Manifestations, Severity and Complications. 12.SARS
CoV2 Exponential Spread and COVID
19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS
CoV2 (COVID
19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS
CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS
CoV2 (COVID
19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS
CoV2 (COVID
19) Novel Variants (DELTA), Vaccine Cross
effectiveness and Durability. 17.SARS
CoV2 (COVID
19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities
Blacks/African Americans (AA). 18.SARS
CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case
positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health
related Event in SARS
CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS
CoV2 (COVID
19) Vaccine Effectiveness and Durability in Immunogenic
related Comorbidities (Multiple Myeloma). 21.SARS
CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS
CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS
CoV2 (COVID
19) Morbidity Implication in Chronic Disease (Type II Diabetes
T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS
CoV2 (COVID
19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS
CoV2 (COVID
19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS
COV
2 (COVID
19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS
CoV2 and COVID
19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo
clustering Differentials in SARS
CoV
2 (COVID
19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
1.Immuno
epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno
epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS
CoV2 (COVID
19): Pandemic and Public Health Emergency Response. 4.SARS
CoV2 Mutation: Immuno
Epidemiologic and Socio
Epidemiologic Response. 5.COVID
19 Pandemic: Epidemic Curve Down
Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS
CoV2 Transmission & COVID
19 Fetal Survivability: Immuno
epidemiologic Perspective. 7.SARS
CoV2 (COVID
19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID
19 Pandemic Global Health Equity Transformation. 9.SARS
CoV2 "Re
emergence" as COVID
19 (2): Translational Public Health and Immuno
epidemiologic Response. 10 .SARS
CoV2 (COVID
19) Viral Dynamics Control. 11.Immune System Senescence in SARS
CoV2 Transmission and COVID
19 Clinical Manifestations, Severity and Complications. 12.SARS
CoV2 Exponential Spread and COVID
19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS
CoV2 (COVID
19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS
CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS
CoV2 (COVID
19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS
CoV2 (COVID
19) Novel Variants (DELTA), Vaccine Cross
effectiveness and Durability. 17.SARS
CoV2 (COVID
19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities
Blacks/African Americans (AA). 18.SARS
CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case
positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health
related Event in SARS
CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS
CoV2 (COVID
19) Vaccine Effectiveness and Durability in Immunogenic
related Comorbidities (Multiple Myeloma). 21.SARS
CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS
CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS
CoV2 (COVID
19) Morbidity Implication in Chronic Disease (Type II Diabetes
T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS
CoV2 (COVID
19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS
CoV2 (COVID
19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS
COV
2 (COVID
19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS
CoV2 and COVID
19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo
clustering Differentials in SARS
CoV
2 (COVID
19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno
epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS
CoV2 (COVID
19): Pandemic and Public Health Emergency Response. 4.SARS
CoV2 Mutation: Immuno
Epidemiologic and Socio
Epidemiologic Response. 5.COVID
19 Pandemic: Epidemic Curve Down
Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS
CoV2 Transmission & COVID
19 Fetal Survivability: Immuno
epidemiologic Perspective. 7.SARS
CoV2 (COVID
19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID
19 Pandemic Global Health Equity Transformation. 9.SARS
CoV2 "Re
emergence" as COVID
19 (2): Translational Public Health and Immuno
epidemiologic Response. 10 .SARS
CoV2 (COVID
19) Viral Dynamics Control. 11.Immune System Senescence in SARS
CoV2 Transmission and COVID
19 Clinical Manifestations, Severity and Complications. 12.SARS
CoV2 Exponential Spread and COVID
19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS
CoV2 (COVID
19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS
CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS
CoV2 (COVID
19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS
CoV2 (COVID
19) Novel Variants (DELTA), Vaccine Cross
effectiveness and Durability. 17.SARS
CoV2 (COVID
19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities
Blacks/African Americans (AA). 18.SARS
CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case
positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health
related Event in SARS
CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS
CoV2 (COVID
19) Vaccine Effectiveness and Durability in Immunogenic
related Comorbidities (Multiple Myeloma). 21.SARS
CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS
CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS
CoV2 (COVID
19) Morbidity Implication in Chronic Disease (Type II Diabetes
T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS
CoV2 (COVID
19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS
CoV2 (COVID
19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS
COV
2 (COVID
19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS
CoV2 and COVID
19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo
clustering Differentials in SARS
CoV
2 (COVID
19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA